License agreement, review of brolucizumab events lead recent retina news
Healio’s top retina/vitreous items this week covered a license agreement between Astellas and 4D Molecular Therapeutics as well as a review of retinal vasculitis or vascular occlusion events following treatment with brolucizumab.
Check out these items and more below.
Image: Adobe Stock
Astellas, 4D Molecular Therapeutics enter license agreement for retinotopic vector
Astellas Pharma and 4D Molecular Therapeutics have entered into a license agreement that grants Astellas the rights to utilize 4DMT’s intravitreal retinotopic R100 vector for treating rare monogenic ophthalmic diseases. Read more.
Most retinal vasculitis, vascular occlusion events after brolucizumab occurred in women
A systematic review of real-world evidence described 70 eyes of 63 patients with retinal vasculitis or vascular occlusion following treatment with brolucizumab for neovascular age-related macular degeneration. Read more.
VRDN-001 for thyroid eye disease promising in phase 1/2 trial
VRDN-001 demonstrated positive preliminary results in the treatment of chronic thyroid eye disease in an ongoing phase 1/2 clinical trial, according to a press release from Viridian Therapeutics. Read more.
BLOG: How retina specialists have used faricimab for wet AMD in the real world
When faricimab became the first bispecific antibody approved by the FDA for use in ophthalmology, retina specialists who treat wet age-related macular degeneration and diabetic macular edema were presented with a new treatment option. Read more.
Bispecifics treatment landscape ‘bustling’ in wet AMD, DME
Bispecific agents appear promising in broadening the treatment landscape in wet age-related macular degeneration and diabetic macular edema, but much remains to be learned about this emerging class of agents. Read more.